
    
      Patients with schizophrenia or schizoaffective disorder who are currently receiving
      antipsychotic medication will be randomly assigned in a double-blind manner to receive either
      D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive
      placebo for 12 weeks.
    
  